Global Partner for Active Pharmaceutical Ingredients, Manufacturing and Supply

Understanding the distinction between an API and a finished dosage form (FDF) is fundamental to pharmaceutical manufacturing.

The active pharma ingredients list spans a broad range of categories, each suited to different drug development needs:

1. Synthetic APIs are chemically synthesised from raw materials through defined reactions. These are among the most widely used active pharmaceutical ingredients, forming the basis of generic and branded medicines.
2. Semi-Synthetic APIs are derived by chemically modifying naturally occurring compounds. Many antibiotics, such as amoxicillin, fall into this category.
3. Biotech-Derived APIs are produced using biological systems, including bacteria, yeast, or mammalian cells. Insulin and certain monoclonal antibodies are examples.
4. High-Potency APIs (HPAPIs) are active at very low doses and are used primarily in oncology. They require specialised containment during manufacturing to ensure worker safety.
5. Speciality APIs include peptides, oligonucleotides, and other complex molecules designed for targeted therapy.

At USV, we invest in research and development of biosimilars, synthetic peptides, and small-molecule generics to meet evolving clinical needs.

The active pharmaceutical ingredient manufacturing process is multi-stage and requires precise execution at every step.

• It begins with research and development, where chemical processes and synthesis routes are identified for a target molecule. This is followed by process development, which optimises reaction conditions for scalability and consistency.
• Raw material sourcing is a critical consideration. The quality of pharmaceutical raw materials and intermediates directly impacts the final API. We operate as a backwards-integrated manufacturing company, maintaining control over sourcing to reduce supply risk.
• Chemical synthesis or biological production then converts starting materials into the active substance through a series of controlled reactions. This is followed by purification, which removes impurities and by-products, bringing the API to the required purity specification.
• Quality testing at multiple stages, including analytical characterisation and stability testing, ensures the API meets pharmacopoeial and regulatory standards.
• Finally, regulatory documentation, including Drug Master Files (DMFs) and compliance dossiers, is prepared to support registration in target markets.

In India, we operate API manufacturing plants at eight locations, equipped with advanced automation technologies that support Industry 4.0 standards.

Quality is not merely a checkpoint in API manufacturing. It is built into every stage of the process.

Good Manufacturing Practice (GMP) governs all aspects of pharmaceutical manufacturing, from personnel and premises to materials, documentation, and quality control.

As defined in regulatory frameworks, GMP is fundamental to ensuring that medicines are consistently produced in accordance with quality standards and that API products meet defined specifications for identity, purity, and potency.

Our manufacturing plants operate under a central quality system, with robust documentation, validation protocols, and continuous process monitoring.

Our regulatory and compliance capabilities support filings across multiple jurisdictions, including the US, Europe, the UK, Australia, and Canada.

Active pharmaceutical ingredients are at the core of treatments across virtually every disease category:

• Diabetes: APIs such as metformin and newer GLP-1 receptor agonists are essential to managing blood glucose in hundreds of millions of patients globally.
• Cardiovascular diseases: The cardiology segment leads the API market, reflecting the high global burden of heart disease.
• Gastroenterology: APIs for acid suppression, inflammatory bowel disease, and digestive disorders support a large patient population worldwide.
• Neurology: Conditions such as epilepsy, Parkinson's disease, Alzheimer's disease, and depression require long-term medication, creating sustained demand for neurological APIs.
• Dermatology: Topical and systemic APIs are used to treat psoriasis, acne, eczema, and skin infections.
• Infectious diseases: Antimicrobials and antivirals remain critical, particularly as antimicrobial resistance drives demand for new and improved formulations.

The global API market is projected to grow from USD 193.15 billion in 2023 to USD 285.29 billion by 2028, based on the rising numbers of chronic diseases and the growing demand for affordable medicines.

Selecting among active pharmaceutical ingredient manufacturers requires careful evaluation across several dimensions.

Manufacturing expertise is foundational. API manufacturing companies in India with deep chemistry capabilities and proven synthesis routes for complex molecules are better positioned to deliver consistent, high-quality products.

Quality systems matter considerably. Look for active pharmaceutical ingredient manufacturers whose plants operate under internationally recognised GMP standards and are regularly inspected by regulatory authorities.

Regulatory capabilities are equally important, particularly for companies supplying regulated markets. The ability to prepare and maintain DMFs and support inspections in multiple jurisdictions reduces time to market.

Supply reliability is essential in any environment. Active pharma ingredients manufacturers with vertically integrated supply chains and domestic sourcing of key starting materials offer greater resilience.

Portfolio breadth allows customers to consolidate their API sourcing with fewer, more capable partners.

USV's wide portfolio spans diabetes, cardiovascular, gastroenterology, and other therapeutic areas, supported by dedicated R&D, API, and FDF sales functions.